{"data":{"id":"us-tx/tex.-government-code-549.0105","jurisdiction":"us-tx","citation":"Tex. Government Code § 549.0105","heading":"REQUIRED DISCLOSURES IN NEGOTIATIONS FOR SUPPLEMENTAL REBATES.","body":"Before or during supplemental rebate agreement negotiations for a prescription drug being considered for the preferred drug list, the commission shall disclose to pharmaceutical manufacturers any clinical edits or clinical protocols that may be imposed on drugs within a particular drug category that are placed on the preferred drug list during the contract period. Clinical edits may not be imposed for a preferred drug during the contract period unless the disclosure is made.\nAdded by Acts 2023, 88th Leg., R.S., Ch. 769 (H.B. 4611), Sec. 1.01, eff. April 1, 2025.","path":["GOVERNMENT CODE","TITLE 4. EXECUTIVE BRANCH","SUBTITLE I. HEALTH AND HUMAN SERVICES","CHAPTER 549. PROVISION OF DRUGS AND DRUG INFORMATION","SUBCHAPTER C. SUPPLEMENTAL REBATES OR PROGRAM BENEFITS FOR PRESCRIPTION DRUGS"],"source_url":"https://statutes.capitol.texas.gov/Docs/GV/htm/GV.549.htm#549.0105","current_through":"89th 2nd Called Legislative Session, 2025","vintage":"","retrieved_at":"2026-08-27T01:47:16Z","sha256":"412f2065a8ba401862223ffdcab201e1fc73b331a1ea58647a88256272008e5e","source_id":"us-tx","stale":false,"prev":"us-tx/tex.-government-code-549.0104","next":"us-tx/tex.-government-code-549.0106"},"notice":"GroundRules: Original legal text. Not legal advice."}